1932

Abstract

Somatic mutations in the isocitrate dehydrogenase () 1 and 2 genes have been described in multiple hematologic and solid tumors, and confer a gain of function, permitting the production of the oncometabolite (R)-2-hydroxyglutarate (2-HG). 2-HG accumulation induces DNA and histone hypermethylation and altered gene expression, ultimately resulting in a block in cellular differentiation. Proof-of-concept preclinical work demonstrated that targeted inhibition of the mutant IDH (mIDH) enzyme is a feasible therapeutic strategy, based on the hypothesis that inhibition of the mIDH enzyme blocks 2-HG production, resulting in an appropriate methylation state and the onset of cellular differentiation. Clinical development programs for targeted inhibitors are underway, and preliminary data in patients with mIDH acute myeloid leukemia suggest that these inhibitors act as differentiation agents. Here we review the use of differentiation agents for the treatment of hematologic and solid tumors and discuss the preclinical and early clinical evidence that mIDH inhibitors mediate antitumor effects through the induction of differentiation.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-cancerbio-050216-122051
2017-03-06
2024-04-14
Loading full text...

Full text loading...

/deliver/fulltext/cancerbio/1/1/annurev-cancerbio-050216-122051.html?itemId=/content/journals/10.1146/annurev-cancerbio-050216-122051&mimeType=html&fmt=ahah

Literature Cited

  1. Al-Ali HK, Jaekel N, Niederwieser D. 2014. The role of hypomethylating agents in the treatment of elderly patients with AML. J. Geriatr. Oncol. 5:89–105 [Google Scholar]
  2. Amary MF, Bacsi K, Maggiani F, Damato S, Halai D. et al. 2011. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J. Pathol 224:334–43 [Google Scholar]
  3. Appleton K, Mackay HJ, Judson I, Plumb JA, McCormick C. et al. 2007. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J. Clin. Oncol. 25:4603–9 [Google Scholar]
  4. Atmaca A, Al-Batran SE, Maurer A, Neumann A, Heinzel T. et al. 2007. Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br. J. Cancer 97:177–82 [Google Scholar]
  5. Birendra KC, DiNardo CD. 2016. Evidence for clinical differentiation and differentiation syndrome in patients with acute myeloid leukemia and IDH1 mutations treated with the targeted mutant IDH1 inhibitor, AG-120. Clin. Lymphoma Myeloma Leuk. 16:460–65 [Google Scholar]
  6. Borodovsky A, Salmasi V, Turcan S, Fabius AW, Baia GS. et al. 2013. 5-Azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. Oncotarget 4:1737–47 [Google Scholar]
  7. Boutzen H, Saland E, Larrue C, de Toni F, Gales L. et al. 2016. Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia. J. Exp. Med. 213:483–97 [Google Scholar]
  8. Braiteh F, Soriano AO, Garcia-Manero G, Hong D, Johnson MM. et al. 2008. Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin. Cancer Res. 14:6296–301 [Google Scholar]
  9. Burke MJ, Lamba JK, Pounds S, Cao X, Ghodke-Puranik Y. et al. 2014. A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia. Am. J. Hematol. 89:889–95 [Google Scholar]
  10. Burnett AK, Russell NH, Hills RK, Bowen D, Kell J. et al. 2015. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol 16:1295–305 [Google Scholar]
  11. Burris H, Mellinghoff I, Maher E, Wen P, Beeram M. et al. 2015. The first reported results of AG-120, a first-in-class potent inhibitor of the IDH1 mutant protein, in a phase 1 study in patients with advanced IDH1-mutant solid tumors, including gliomas. Mol. Cancer Ther. 14:12 Suppl. 2PL04–05 (Abstr.) [Google Scholar]
  12. Cairns RA, Iqbal J, Lemonnier F, Kucuk C, de Leval L. et al. 2012. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood 119:1901–3 [Google Scholar]
  13. Chen C, Liu Y, Lu C, Cross JR, Morris JP 4th. et al. 2013. Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. Genes Dev 27:1974–85 [Google Scholar]
  14. Chowdhury R, Yeoh KK, Tian YM, Hillringhaus L, Bagg EA. et al. 2011. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep 12:463–69 [Google Scholar]
  15. Cimino G, Lo-Coco F, Fenu S, Travaglini L, Finolezzi E. et al. 2006. Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia. Cancer Res 66:8903–11 [Google Scholar]
  16. Coombs CC, Tavakkoli M, Tallman MS. 2015. Acute promyelocytic leukemia: where did we start, where are we now, and the future. Blood Cancer J 5:e304 [Google Scholar]
  17. Cortes JE, Kantarjian H, Foran JM, Ghirdaladze D, Zodelava M. et al. 2013. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. J. Clin. Oncol. 31:3681–87 [Google Scholar]
  18. Cortes JE, Kantarjian H, Kadia TM, Borthakur G, Konopleva M. et al. 2016. Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML. J. Clin. Oncol. 34:Suppl.7008 (Abstr.) [Google Scholar]
  19. Cortes JE, Perl AE, Dombret H, Kayser S, Steffen B. et al. 2012. Final results of a phase 2 open-label, monotherapy efficacy and safety study of quizartinib (AC220) in patients ≥60 years of age with FLT3 ITD positive or negative relapsed/refractory acute myeloid leukemia. Blood 120:2148 (Abstr.) [Google Scholar]
  20. Cruz FD, Matushansky I. 2012. Solid tumor differentiation therapy—is it possible. Oncotarget 3:559–67 [Google Scholar]
  21. Dang L, White DW, Gross S, Bennett BD, Bittinger MA. et al. 2009. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462:739–44 [Google Scholar]
  22. Dang L, Yen K, Attar EC. 2016. IDH mutations in cancer and progress toward development of targeted therapeutics. Ann. Oncol. 27:599–608 [Google Scholar]
  23. Daskalakis M, Nguyen TT, Nguyen C, Guldberg P, Kohler G. et al. 2002. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2′-deoxycytidine (decitabine) treatment. Blood 100:2957–64 [Google Scholar]
  24. de Botton S, Pollyea DA, Stein EM, DiNardo CD, Fathi AT. et al. 2015. Clinical safety and activity of AG-120, a first-in-class, potent inhibitor of the IDH1 mutant protein, in a phase 1 study of patients with advanced IDH1-mutant hematologic malignancies. Haematologica 100:Suppl. 1P563 (Abstr.) [Google Scholar]
  25. DiNardo CD, de Botton S, Pollyea DA, Stein EM, Fathi AM. et al. 2015a. Molecular profiling and relationship with clinical response in patients with IDH1 mutation-positive hematologic malignancies receiving AG-120, a first-in-class potent inhibitor of mutant IDH1, in addition to data from the completed dose escalation portion of the phase 1 study. Blood 126:231306 (Abstr.) [Google Scholar]
  26. DiNardo CD, de Botton S, Stein EM, Roboz GJ, Swords RT. et al. 2016. Determination of IDH1 mutational burden and clearance via next-generation sequencing in patients with IDH1 mutation-positive hematologic malignancies receiving AG-120, a first-in-class inhibitor of mutant IDH1. BloodIn press (Abstr.)
  27. DiNardo CD, Propert KJ, Loren AW, Paietta E, Sun Z. et al. 2013. Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood 121:4917–24 [Google Scholar]
  28. DiNardo CD, Ravandi F, Agresta S, Konopleva M, Takahashi K. et al. 2015b. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. Am. J. Hematol. 90:732–36 [Google Scholar]
  29. Efficace F, Mandelli F, Avvisati G, Cottone F, Ferrara F. et al. 2014. Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomes. J. Clin. Oncol. 32:3406–12 [Google Scholar]
  30. Eghtedar A, Rodriguez I, Kantarjian H, O'Brien S, Daver N. et al. 2015. Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide. Leuk. Lymphoma 56:1342–45 [Google Scholar]
  31. Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S. et al. 2006. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 107:3469–73 [Google Scholar]
  32. Fan B, Chen Y, Wang F, Yen K, Utley L. et al. 2015. Pharmacokinetic/pharmacodynamic (PK/PD) evaluation of AG-221, a potent mutant IDH2 inhibitor, from a phase 1 trial of patients with IDH2-mutation positive hematologic malignancies. Haematologica 100:Suppl. 1E948 (Abstr.) [Google Scholar]
  33. Fandy TE, Herman JG, Kerns P, Jiemjit A, Sugar EA. et al. 2009. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 114:2764–73 [Google Scholar]
  34. Fathi AT, Sadrzadeh H, Borger DR, Ballen KK, Amrein PC. et al. 2012. Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. Blood 120:4649–52 [Google Scholar]
  35. Fathi AT, Sadrzadeh H, Comander AH, Higgins MJ, Bardia A. et al. 2014. Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate. Oncologist 19:602–7 [Google Scholar]
  36. Ferrara FF, Fazi F, Bianchini A, Padula F, Gelmetti V. et al. 2001. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res 61:2–7 [Google Scholar]
  37. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J. et al. 2010. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18:553–67 [Google Scholar]
  38. Fredly H, Gjertsen BT, Bruserud O. 2013. Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents. Clin. Epigenet. 5:12 [Google Scholar]
  39. Frohlich E, Wahl R. 2015. Chemotherapy and chemoprevention by thiazolidinediones. Biomed. Res. Int 2015:845340 [Google Scholar]
  40. Garcia-Manero G, Atallah E, Khaled SK, Arellano ML, Patnaik MM. et al. 2015a. Final results from a phase 2 study of pracinostat in combination with azacitidine in elderly patients with acute myeloid leukemia (AML). Blood 126:23453 (Abstr.) [Google Scholar]
  41. Garcia-Manero G, Berdeja JG, Komrokji RS, Essell J, Lyons RM. et al. 2015b. A randomized, placebo-controlled, phase II study of pracinostat in combination with azacitidine (AZA) in patients with previously untreated myelodysplastic syndrome (MDS). Blood 126:23911 (Abstr.) [Google Scholar]
  42. Garcia-Manero G, Tambaro FP, Bekele NB, Yang H, Ravandi F. et al. 2012. Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. J. Clin. Oncol. 30:2204–10 [Google Scholar]
  43. Ghiam AF, Cairns RA, Thoms J, Dal Pra A, Ahmed O. et al. 2012. IDH mutation status in prostate cancer. Oncogene 31:3826 [Google Scholar]
  44. Glasspool RM, Brown R, Gore ME, Rustin GJ, McNeish IA. et al. 2014. A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin versus carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer. Br. J. Cancer 110:1923–29 [Google Scholar]
  45. Gore SD, Baylin S, Sugar E, Carraway H, Miller CB. et al. 2006. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 66:6361–69 [Google Scholar]
  46. Gore SD, Fenaux P, Santini V, Bennett JM, Silverman LR. et al. 2013. A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica 98:1067–72 [Google Scholar]
  47. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A. et al. 2001. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20:6969–78 [Google Scholar]
  48. Grishina O, Schmoor C, Dohner K, Hackanson B, Lubrich B. et al. 2015. DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acute myeloid leukemia who are ineligible for induction chemotherapy. BMC Cancer 15:430 [Google Scholar]
  49. Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA. et al. 2010. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J. Exp. Med. 207:339–44 [Google Scholar]
  50. Hansen E, Quivoron C, Straley K, Lemieux R, Popovici-Muller J. et al. 2014. AG-120, an oral, selective, first-in-class, potent inhibitor of mutant IDH1, reduces intracellular 2HG and induces cellular differentiation in TF-1 R132H cells and primary human IDH1 mutant AML patient samples treated ex vivo. Blood 124:213734 (Abstr.) [Google Scholar]
  51. He J, Xiu L, De Porre P, Dass R, Thomas X. 2015. Decitabine reduces transfusion dependence in older patients with acute myeloid leukemia: results from a post hoc analysis of a randomized phase III study. Leuk. Lymphoma 56:1033–42 [Google Scholar]
  52. Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A. et al. 2016. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J. Clin. Oncol. 34:1510–17 [Google Scholar]
  53. Hollenbach PW, Nguyen AN, Brady H, Williams M, Ning Y. et al. 2010. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLOS ONE 5:e9001 [Google Scholar]
  54. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX. et al. 1988. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72:567–72 [Google Scholar]
  55. Intlekofer AM, Dematteo RG, Venneti S, Finley LW, Lu C. et al. 2015. Hypoxia induces production of L-2-hydroxyglutarate. Cell Metab 22:304–11 [Google Scholar]
  56. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D. et al. 2004. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103:1635–40 [Google Scholar]
  57. Issa JP, Garcia-Manero G, Huang X, Cortes J, Ravandi F. et al. 2015. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer 121:556–61 [Google Scholar]
  58. Johnston P, Cashen AF, Nikolinakos PG, Beaven AW, Barta SG. et al. 2015. Safe and effective treatment of patients with peripheral T-cell lymphoma (PTCL) with the novel HDAC inhibitor, belinostat, in combination with CHOP: results of the Bel-CHOP Phase 1 trial. Blood 126:23253 (Abstr.) [Google Scholar]
  59. Juergens RA, Wrangle J, Vendetti FP, Murphy SC, Zhao M. et al. 2011. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov 1:598–607 [Google Scholar]
  60. Juratli TA, Kirsch M, Robel K, Soucek S, Geiger K. et al. 2012. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas. J. Neurooncol. 108:403–10 [Google Scholar]
  61. Kernytsky A, Wang F, Hansen E, Schalm S, Straley K. et al. 2015. IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition. Blood 125:296–303 [Google Scholar]
  62. Kipp BR, Voss JS, Kerr SE, Barr Fritcher EG, Graham RP. et al. 2012. Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum. Pathol. 43:1552–58 [Google Scholar]
  63. Kirschbaum MH, Foon KA, Frankel P, Ruel C, Pulone B. et al. 2014. A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study. Leuk. Lymphoma 55:2301–4 [Google Scholar]
  64. Kosmider O, Gelsi-Boyer V, Slama L, Dreyfus F, Beyne-Rauzy O. et al. 2010. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia 24:1094–96 [Google Scholar]
  65. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE. et al. 2001. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98:1752–59 [Google Scholar]
  66. Kuendgen A, Bug G, Ottmann OG, Haase D, Schanz J. et al. 2011. Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid. Clin. Epigenet. 2:389–99 [Google Scholar]
  67. Lass U, Numann A, von Eckardstein K, Kiwit J, Stockhammer F. et al. 2012. Clonal analysis in recurrent astrocytic, oligoastrocytic and oligodendroglial tumors implicates IDH1- mutation as common tumor initiating event. PLOS ONE 7:e41298 [Google Scholar]
  68. Levis M, Perl A, Dombret H, Döhner H, Steffen B. et al. 2012. Final results of a phase 2 open-label, monotherapy efficacy and safety study of quizartinib (AC220) in patients with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia after second-line chemotherapy or hematopoietic stem cell transplantation. Blood 120:21673 (Abstr.) [Google Scholar]
  69. Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM. et al. 2013. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N. Engl. J. Med. 369:111–21 [Google Scholar]
  70. Lopez GY, Reitman ZJ, Solomon D, Waldman T, Bigner DD. et al. 2010. IDH1R132 mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain. Biochem. Biophys. Res. Commun. 398:585–87 [Google Scholar]
  71. Losman JA, Looper RE, Koivunen P, Lee S, Schneider RK. et al. 2013. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 339:1621–25 [Google Scholar]
  72. Lu C, Venneti S, Akalin A, Fang F, Ward PS. et al. 2013. Induction of sarcomas by mutant IDH2. Genes Dev 27:1986–98 [Google Scholar]
  73. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S. et al. 2012. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483:474–78 [Google Scholar]
  74. Man CH, Fung TK, Ho C, Han HH, Chow HC. et al. 2012. Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. Blood 119:5133–43 [Google Scholar]
  75. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD. et al. 2009. Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 361:1058–66 [Google Scholar]
  76. McKenna HJ, de Vries P, Brasel K, Lyman SD, Williams DE. 1995. Effect of flt3 ligand on the ex vivo expansion of human CD34+ hematopoietic progenitor cells. Blood 86:3413–20 [Google Scholar]
  77. Meldi K, Qin T, Buchi F, Droin N, Sotzen J. et al. 2015. Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia. J. Clin. Invest. 125:1857–72 [Google Scholar]
  78. Mi JQ, Chen SJ, Zhou GB, Yan XJ, Chen Z. 2015. Synergistic targeted therapy for acute promyelocytic leukaemia: a model of translational research in human cancer. J. Intern. Med. 278:627–42 [Google Scholar]
  79. Molenaar RJ, Thota S, Nagata Y, Patel B, Clemente M. et al. 2015. Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms. Leukemia 29:2134–42 [Google Scholar]
  80. Moussaieff A, Rouleau M, Kitsberg D, Cohen M, Levy G. et al. 2015. Glycolysis-mediated changes in acetyl-CoA and histone acetylation control the early differentiation of embryonic stem cells. Cell Metab 21:392–402 [Google Scholar]
  81. Mund C, Hackanson B, Stresemann C, Lubbert M, Lyko F. 2005. Characterization of DNA demethylation effects induced by 5-aza-2′-deoxycytidine in patients with myelodysplastic syndrome. Cancer Res 65:7086–90 [Google Scholar]
  82. Munster P, Marchion D, Bicaku E, Schmitt M, Lee JH. et al. 2007. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J. Clin. Oncol. 25:1979–85 [Google Scholar]
  83. Nakamura K, Nakabayashi K, Htet Aung K, Aizawa K, Hori N. et al. 2015. DNA methyltransferase inhibitor zebularine induces human cholangiocarcinoma cell death through alteration of DNA methylation status. PLOS ONE 10:e0120545 [Google Scholar]
  84. Navada SC, Steinmann J, Lubbert M, Silverman LR. 2014. Clinical development of demethylating agents in hematology. J. Clin. Invest. 124:40–46 [Google Scholar]
  85. Nervi C, De Marinis E, Codacci-Pisanelli G. 2015. Epigenetic treatment of solid tumours: a review of clinical trials. Clin. Epigenet. 7:127 [Google Scholar]
  86. Niu C, Yan H, Yu T, Sun HP, Liu JX. et al. 1999. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 94:3315–24 [Google Scholar]
  87. O'Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P. et al. 2015. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J. Clin. Oncol. 33:2492–99 [Google Scholar]
  88. Ohgaki H, Kleihues P. 2013. The definition of primary and secondary glioblastoma. Clin. Cancer Res. 19:764–72 [Google Scholar]
  89. Oldham WM, Clish CB, Yang Y, Loscalzo J. 2015. Hypoxia-mediated increases in L-2-hydroxyglutarate coordinate the metabolic response to reductive stress. Cell Metab 22:291–303 [Google Scholar]
  90. Parker SJ, Metallo CM. 2015. Metabolic consequences of oncogenic IDH mutations. Pharmacol. Ther. 152:54–62 [Google Scholar]
  91. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ. et al. 2008. An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807–12 [Google Scholar]
  92. Platta CS, Greenblatt DY, Kunnimalaiyaan M, Chen H. 2007. The HDAC inhibitor trichostatin A inhibits growth of small cell lung cancer cells. J. Surg. Res. 142:219–26 [Google Scholar]
  93. Pollyea DA, DiNardo CD, Thirman MJ, Letai A, Wei AH. et al. 2016. Results of a phase 1b study of venetoclax plus decitabine or azacitidine in untreated acute myelogenous leukemia patients ≥65 years ineligible for standard induction therapy. J. Clin. Oncol. 34:Suppl.7009 (Abstr.) [Google Scholar]
  94. Prost S, Relouzat F, Spentchian M, Ouzegdouh Y, Saliba J. et al. 2015. Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists. Nature 525:380–83 [Google Scholar]
  95. Quivoron C, David M, Straley K, Travins J, Kim H. et al. 2014. AG-221, an oral, selective, first-in-class, potent ID. H2–R10Q mutant inhibitor, induces differentiation in a xenotransplant model. Blood 124:213735 (Abstr.) [Google Scholar]
  96. Raffoux E, Cras A, Recher C, Boelle PY, de Labarthe A. et al. 2010. Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. Oncotarget 1:34–42 [Google Scholar]
  97. Ravandi F, Arana Yi C, Cortes JE, Levis M, Faderl S. et al. 2014. Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia. Leukemia 28:1543–45 [Google Scholar]
  98. Razak AR, Hotte SJ, Siu LL, Chen EX, Hirte HW. et al. 2011. Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours. Br. J. Cancer 104:756–62 [Google Scholar]
  99. Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R. et al. 1998. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. PNAS 95:3003–7 [Google Scholar]
  100. Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C. et al. 2013. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340:626–30 [Google Scholar]
  101. Rollig C, Serve H, Huttmann A, Noppeney R, Muller-Tidow C. et al. 2015. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol 16:1691–99 [Google Scholar]
  102. Rosnet O, Buhring HJ, Marchetto S, Rappold I, Lavagna C. et al. 1996. Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia 10:238–48 [Google Scholar]
  103. Rusten LS, Lyman SD, Veiby OP, Jacobsen SE. 1996. The FLT3 ligand is a direct and potent stimulator of the growth of primitive and committed human CD34+ bone marrow progenitor cells in vitro. Blood 87:1317–25 [Google Scholar]
  104. Saha SK, Parachoniak CA, Ghanta KS, Fitamant J, Ross KN. et al. 2014. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. Nature 513:110–14 [Google Scholar]
  105. Sanz MA, Montesinos P. 2014. How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia. Blood 123:2777–82 [Google Scholar]
  106. Sasaki M, Knobbe CB, Munger JC, Lind EF, Brenner D. et al. 2012. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 488:656–59 [Google Scholar]
  107. Saunthararajah Y, Triozzi P, Rini B, Singh A, Radivoyevitch T. et al. 2012. p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies. Semin. Oncol. 39:97–108 [Google Scholar]
  108. Sequist LV, Heist RS, Shaw AT, Fidias P, Rosovsky R. et al. 2011. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann. Oncol. 22:2616–24 [Google Scholar]
  109. Serve H, Krug U, Wagner R, Sauerland MC, Heinecke A. et al. 2013. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J. Clin. Oncol. 31:3110–18 [Google Scholar]
  110. Sexauer A, Perl A, Yang X, Borowitz M, Gocke C. et al. 2012. Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML. Blood 120:4205–14 [Google Scholar]
  111. Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM. et al. 2004. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. PNAS 101:5328–35 [Google Scholar]
  112. Shih A, Shank KR, Meydan C, Intlekofer AM, Ward P. et al. 2014. AG-221, a small molecule mutant IDH2 inhibitor, remodels the epigenetic state of IDH2-mutant cells and induces alterations in self-renewal/differentiation in IDH2-mutant AML model in vivo. Blood 124:21437 (Abstr.) [Google Scholar]
  113. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J. et al. 2006. The consensus coding sequences of human breast and colorectal cancers. Science 314:268–74 [Google Scholar]
  114. Small D, Levenstein M, Kim E, Carow C, Amin S. et al. 1994. STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. PNAS 91:459–63 [Google Scholar]
  115. Soriano AO, Yang H, Faderl S, Estrov Z, Giles F. et al. 2007. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 110:2302–8 [Google Scholar]
  116. Stein EM, DiNardo CD, Altman JK, Collins R, DeAngelo DJ. et al. 2015. Safety and efficacy of AG-221, a potent inhibitor of mutant IDH2 that promotes differentiation of myeloid cells in patients with advanced hematologic malignancies: results of a phase 1/2 trial. Blood 126:23323 (Abstr.) [Google Scholar]
  117. Stein EM, Tallman MS. 2016. Emerging therapeutic drugs for AML. Blood 127:71–78 [Google Scholar]
  118. Stirewalt DL, Radich JP. 2003. The role of FLT3 in haematopoietic malignancies. Nat. Rev. Cancer 3:650–65 [Google Scholar]
  119. Stone RM, Mandrekar S, Sanford BL, Geyer S, Bloomfield CD. et al. 2015. The multi-kinase inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combination with daunorubicin (D)/cytarabine (C) induction (ind), high-dose C consolidation (consol), and as maintenance (maint) therapy in newly diagnosed acute myeloid leukemia (AML) patients (pts) age 18–60 with FLT3 mutations (muts): an international prospective randomized (rand), P-controlled double-blind trial (CALGB 10603/RATIFY [Alliance]). Blood 126:236 (Abstr.) [Google Scholar]
  120. Stresemann C, Lyko F. 2008. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int. J. Cancer 123:8–13 [Google Scholar]
  121. Tassara M, Dohner K, Brossart P, Held G, Gotze K. et al. 2014. Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients. Blood 123:4027–36 [Google Scholar]
  122. Tefferi A, Jimma T, Sulai NH, Lasho TL, Finke CM. et al. 2012. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia 26:475–80 [Google Scholar]
  123. Testa U, Lo-Coco F. 2015. Targeting of leukemia-initiating cells in acute promyelocytic leukemia. Stem Cell Investig 2:8 [Google Scholar]
  124. Thol F, Weissinger EM, Krauter J, Wagner K, Damm F. et al. 2010. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica 95:1668–74 [Google Scholar]
  125. Turcan S, Fabius AW, Borodovsky A, Pedraza A, Brennan C. et al. 2013. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT inhibitor decitabine. Oncotarget 4:1729–36 [Google Scholar]
  126. Wander SA, Levis MJ, Fathi AT. 2014. The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond. Ther. Adv. Hematol. 5:65–77 [Google Scholar]
  127. Wang F, Travins J, DeLaBarre B, Penard-Lacronique V, Schalm S. et al. 2013. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 340:622–26 [Google Scholar]
  128. Wang ZY, Chen Z. 2008. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 111:2505–15 [Google Scholar]
  129. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. 2009. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am. J. Pathol. 174:1149–53 [Google Scholar]
  130. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O. et al. 2009. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15:7412–20 [Google Scholar]
  131. Wouters BJ, Delwel R. 2016. Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia. Blood 127:42–52 [Google Scholar]
  132. Xu W, Yang H, Liu Y, Yang Y, Wang P. et al. 2011. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 19:17–30 [Google Scholar]
  133. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA. et al. 2009. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med 360:765–73 [Google Scholar]
  134. Yanada M, Matsuo K, Suzuki T, Kiyoi H, Naoe T. 2005. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. Leukemia 19:1345–49 [Google Scholar]
  135. Yang AS, Doshi KD, Choi SW, Mason JB, Mannari RK. et al. 2006. DNA methylation changes after 5-aza-2′-deoxycytidine therapy in patients with leukemia. Cancer Res 66:5495–503 [Google Scholar]
  136. Zhang XW, Yan XJ, Zhou ZR, Yang FF, Wu ZY. et al. 2010. Arsenic trioxide controls the fate of the PML-RARα oncoprotein by directly binding PML. Science 328:240–43 [Google Scholar]
  137. Zhao S, Lin Y, Xu W, Jiang W, Zha Z. et al. 2009. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1α. Science 324:261–65 [Google Scholar]
  138. Zhu H, Hu J, Chen L, Zhou W, Li X. et al. 2014. Long-term follow-up of survival, complications, arsenic retention and quality of life in patients with newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid/arsenic trioxide combination therapy. Blood 124:21282 (Abstr.) [Google Scholar]
  139. Zhu HH, Wu DP, Jin J, Li JY, Ma J. et al. 2013. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial. J. Clin. Oncol. 31:4215–21 [Google Scholar]
  140. Zinzani PL, Bonthapally V, Huebner D, Lutes R, Chi A, Pileri S. 2016. Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: cutaneous T-cell lymphomas. Crit. Rev. Oncol. Hematol. 99:228–40 [Google Scholar]
/content/journals/10.1146/annurev-cancerbio-050216-122051
Loading
/content/journals/10.1146/annurev-cancerbio-050216-122051
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error